Gene responsible for rare body-fat disorder identified

An international team of researchers led by scientists at UT Southwestern Medical Center at Dallas have identified the gene that causes a rare body-fat disorder, a discovery that may ultimately expand the understanding of obesity-related illnesses.

The researchers report that the disorder, congenital generalised lipodystrophy (CGL), or the extreme lack of body fat at birth, occurs as a result of mutations in the AGPAT2 gene, which is involved in the production of fat. This is the first documented human disorder that disrupts the biochemical pathway of fat synthesis.

"Now we know why patients with congenital generalised lipodystrophy are unable to synthesise fat in a normal fashion," said Dr Abhimanyu Garg, professor of internal medicine and chief of nutrition and metabolic diseases at UT Southwestern and senior author of the study. "Even though this is a rare disease affecting approximately one in 12.5 million people, our findings may have implications to the understanding of insulin-resistance disorders and common forms of obesity."

The mutated form of the AGPAT2 gene was identified in the 11 families that participated in the study. Characterised by partial or complete lack of body fat at birth, individuals affected by this disorder develop severe diabetes as teenagers. Other complications include severe insulin resistance, high blood lipids and an accumulation of fat in the liver.

"Although we understand how an abnormal AGPAT2 gene may cause lack of body fat, we still need to study how the abnormal gene leads to severe insulin resistance, diabetes, high blood lipids and fatty liver," said Dr Anil Agarwal, assistant professor of internal medicine and lead author of the study.

Dr Garg said, "It is very possible that some abnormalities in the genes involved in the pathway of fat synthesis can cause increased fat deposition and obesity. The identification of this gene will allow us to better define the normal role of genes involved in the growth and development of body fat during embryonic life and at the start of puberty."

"We will also elucidate how these genetic abnormalities affect the action of insulin on the fat cells, liver and muscle, which will lead to a better understanding of how common types of obesity cause insulin resistance and other metabolic complications."

Item provided courtesy of The University of Texas Southwestern Medical Centre